The committee will meet in open session to discuss EUA of the Janssen Biotech Inc. COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years and older.
However I don’t know if that’s the headliner and there are opening acts, so to say. There is also a meeting March 5 which seems much more likely we would be able to submit our information in time for. If you look at their submission process I don’t think we could make it by then. March 5 even seems soon.